SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to widespread reports of users experiencing outages and technical issues, sparking frustration and concerns about the platform's reliability; some users are unable to access their accounts or execute trades. The issues are reportedly tied to a larger Amazon Web Services (AWS) outage, but the community is still expressing distrust and considering alternative platforms. Despite the technical difficulties, the stock price is up, leading to confusion and speculation about market manipulation.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GME is trending as some traders draw comparisons to BYND's recent surge, speculating whether GME could see a similar short squeeze; the community is actively discussing prior squeezes and potential catalysts. Some investors express frustration with GME's performance, while others remain optimistic about its long-term potential amid growing discussions around meme stocks and short squeeze opportunities.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending amid discussions about AI competition and its potential impact on Google's search dominance, with investors weighing the implications of new AI browser technologies. Community members are also focused on Google's AI investments and potential partnerships, particularly regarding its cloud infrastructure and Gemini AI model. Positive analyst ratings and potential earnings run-ups are contributing to the stock's current momentum.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to renewed community interest, possibly driven by its recent surpassing of a one-year high and BTIG adjusting their stance to a Buy rating with a target price of $40. Community members are actively discussing potential catalysts and upcoming opportunities related to the stock's momentum. The company's focus on novel therapies for immune-related diseases and recent financing updates may also contribute to the heightened attention.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following strong earnings and procedure growth, particularly with the da Vinci 5 system. The community is weighing the impact of tariffs and margin pressures against the company's long-term growth potential and market dominance in robotic surgery. Bullish sentiment is fueled by raised guidance and analysts' price targets, while some caution against high valuation and potential market volatility.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to a mixed Q3 earnings report and cautious forward guidance, sparking concerns about the near-term outlook despite a strong analog chip performance. Community discussions center on whether this drop represents a buying opportunity or signals deeper industry headwinds, with some analysts questioning the capital expenditure plan. Investors are also monitoring tariff implications and potential shifts in market share amid evolving US-China trade dynamics.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's upcoming earnings and Elon Musk's compensation plan are driving much of the current discussion. Community members are actively debating potential earnings outcomes, forward guidance, and the impact of Musk's pay package on shareholder value and stock performance. Additionally, some traders point to technical indicators and unusual options activity as potential signals for the stock's direction.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

$NERV is trending due to a significant financing deal aimed at advancing its schizophrenia treatment through Phase 3 trials, sparking excitement among retail investors. Community discussions revolve around the potential FDA catalyst and the stock's potential for further gains. The stock's substantial pre-market surge and high trading volume reflect the market's reaction to the news and the renewed focus on the company's prospects in the biotech sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending following the announcement of its acquisition of Railbird, signaling a move into prediction markets beyond sports betting, with the launch of DraftKings Predictions. Community discussions revolve around whether this strategic shift will drive growth or if DraftKings is late to the game, while also debating its impact on existing sports betting licenses and competition with prediction market platforms.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Six Flags ($FUN) is trending after NFL star Travis Kelce reportedly teamed up with activist investor Jana Partners to push for company changes. The community speculates about potential marketing strategies involving Kelce's fiance, Taylor Swift, while some express skepticism about the company's long-term prospects despite the recent investment news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders

Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders PR Newswire NEW YORK, Oct. 21, 2025 NEW...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR, VRNT, and MRUS

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR, VRNT, and MRUS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR...

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders PR...

Viking Therapeutics jumped to the top of Stocktwits’ trending tickers after a burst of weekend retail chatter tied to deal speculation, rotation flows out of Eli Lilly, and near-term trial milestones.&nbsp;The stock traded nearly 4% higher in overnight trade on Sunday, while retail sentiment was ‘bullish’ amid ‘normal’ message volume.Users pointed to profit-taking in large caps and rotation into Viking, floated the idea of a potential approach from Lilly, and argued that shares are being re-rated since Metsera’s buyout&nbsp;by Pfizer created a perceived price floor for peers.Several&nbsp;watchers on Stocktwits highlighted the company’s next catalyst path. Interest centered on the planned subcutaneous-to-oral maintenance study, which CEO Brian Lian said on a Bernstein call is slated to begin “late this quarter or early next quarter.”&nbsp;Some saw intrigue in the design and flagged a possible “sell-the-news” setup, while others anticipated updates on spend and Phase 3 enrollment on the upcoming earnings call and kept partnership or buyout scenarios “in play.”<stembedurl>https://stocktwits.com/saifnila2/message/631119435</stembedurl><stembedurl>https://stocktwits.com/saifnila2/message/631074611</stembedurl>Last month,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/viking-therapeutics-stock-boost-pfizer-metsera-deal-btig-retail-slams-rivals-inferior-pipelines/chDhieAR3P5">BTIG suggested that Viking is benefiting from Pfizer’s agreement</a> to acquire Metsera, which expands Big Pharma's appetite for cardiometabolic assets. The research firm reiterated its ‘Buy’ rating with a $125 target, citing sharpened strategic optionality following recent M&amp;A, while Roche’s takeover of 89bio reinforced expectations for continued deal activity across the obesity and NASH pipelines.Retail voices remained split on strategy. Some argued Viking should not “go it alone,” given its lean headcount and would be better served by a larger commercial partner. Others framed the setup more broadly, citing pipeline breadth, potential rate-cut tailwinds, patent positioning, and a “David vs Goliath” narrative that could keep both institutions and retail engaged.<stembedurl>https://stocktwits.com/Reaperofmars1/message/631069156</stembedurl><stembedurl>https://stocktwits.com/LastResort/message/631074413</stembedurl>Investors also revisited&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/viking-short-interest-hits-5-year-high-after-weight-loss-drug-stumble/chss46sRdKN">the August data on oral VK2735</a>, noting a double-digit mean weight loss at 13 weeks, with tolerability viewed as manageable,&nbsp;although not as pristine as in the early studies.&nbsp;Several analysts, including B. Riley, Leerink, Jefferies, Stifel, and JPMorgan, called the selloff that followed overdone, emphasizing dose flexibility, maintenance positioning, and the potential to modulate gastrointestinal events through slower titration.<a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 26% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts 

Shares rose nearly 4% overnight as investors tied Viking’s upcoming trial and its positioning to renewed obesity-drug deal momentum after Pfizer’s Metsera buyout.

Equity

Can PFE Successfully Return to the Obesity Space With Metsera Buyout?

Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.

Company News for Sep 23, 2025

Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.

Shares of Viking Therapeutics rose 3.4% to $26.25 on Monday and extended gains after hours,&nbsp;with a Wall Street research firm suggesting the biopharma is benefiting from Pfizer’s buyout offer for Metsera as it looks to bolster its obesity drug pipeline.BTIG reiterated a ‘Buy’ rating and $125 price target on&nbsp;Viking’s stock, saying the transaction sharpens&nbsp;the company’s&nbsp;clinical updates and strategic optionality while bolstering sentiment ahead of key readouts. The commentary followed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/89bio-stock-surges-roche-3-5b-buyout-wall-street-analyst-cautious/chDdNVaR3br">Roche’s acquisition of 89bio</a>, signaling increased deal activity in the biotech space.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> surged to an all-time high Monday, marking their biggest one-day gain ever.&nbsp;As part of the deal, Pfizer will pay Metsera $47.50 in cash per share, giving the company an enterprise value of $4.9 billion. If three clinical milestones are achieved, additional payments of $22.50 per Metsera share will be made, bringing the total value of the deal to as much as $7.3 billion. The deal is expected to close in the fourth quarter of 2025, pending approvals.Metsera, a clinical-stage biotech developing therapies for obesity and cardiometabolic diseases, will add four differentiated programs to Pfizer's pipeline. The assets include weekly and monthly injectable GLP-1 receptor agonists, two orally delivered GLP-1 candidates, and MET-233i, a monthly injectable amylin analog. The company previously discontinued its own obesity candidate Danuglipron.Viking was also in the spotlight, with Daniel Newman, CEO of Futurum Equities,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/danielnewmanUV/status/1970178447411683535">posting on X</a> that Viking’s valuation “just got a massive shot in the arm with the Pfizer deal to buy Metsera,” describing Metsera’s GLP-1 program as “a far less exciting GLP” and arguing that Viking is “worth far more than $7.2 billion.”On Stocktwits, retail sentiment was ‘extremely bullish’ for both Pfizer and Metsera amid ‘extremely high’ message volume, while Viking drew ‘bullish’ sentiment alongside ‘high’ activity.One bullish user said Viking management had likely rejected lowball offers from large pharma, leaving rivals to acquire ‘inferior pipelines.<stembedurl>https://stocktwits.com/deerhtide/message/629602680</stembedurl>Another pointed to debate over whether Viking should pursue a buyout or go-it-alone strategy, adding that CEO Brian Lian’s stake of more than two million shares aligns him with investors. The user disclosed holding 83,000 shares, calling the position conviction-driven.<stembedurl>https://stocktwits.com/SauceMan912/message/629604221</stembedurl>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> is down 4.5%, Metsera’s shares have more than doubled, and&nbsp;<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics’ stock</a> has fallen 34.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

U.S. equities gained in Monday’s afternoon trade amid a surge in big tech stocks like Nvidia Corp. (NVDA), Apple Inc. (AAPL), and Oracle Corp. (ORCL), erasing the weakness observed during the morning session.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.41% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, rose 0.54%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, gained 0.13%.Here are the top stocks making the biggest moves in Monday’s afternoon trade:<a href="https://stocktwits.com/symbol/NVDA">Nvidia Corp. (NVDA)</a>Nvidia’s shares were up nearly 4% in Monday’s afternoon session, hitting an all-time high, after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-plans-100-billion-investment-to-build-10-gw-network-with-openai/chDQM6aR32p">announced</a> that it will invest up to $100 billion in OpenAI as part of a new partnership with the AI startup. Nvidia will supply and finance at least 10 gigawatts of advanced computing systems for the development of OpenAI’s next-generation AI models.<a href="https://stocktwits.com/symbol/NVDA">NVDA stock</a> is up 36% year-to-date.<a href="https://stocktwits.com/symbol/MTSR">Metsera Inc. (MTSR)</a>Metsera shares were up by over 62% in Monday’s afternoon trade after Pfizer Inc. (PFE)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/metsera-stock-surges-pre-market-after-pfizer-confirms-acquisition/chDQNVhR3cy">announced</a> that it will acquire the former for an upfront payment of $4.9 billion. Pfizer will pay $47.50 per share for Metsera, and it has also promised a bonus payment of $22.50 per share if Metsera’s drugs hit certain milestones.<a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> is up 112% year-to-date.<a href="https://stocktwits.com/symbol/ORCL">Oracle Corp. (ORCL)</a>Oracle shares were up nearly 5% in Monday’s afternoon trade after a White House official&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-government-wont-have-any-take-equity-stake-in-tiktok-new-entity/chDQsItR32F">confirmed</a> that the company would provide security and help oversee the recreation of a U.S. version of TikTok. Oracle also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-clay-magouyrk-mike-sicilia-co-ceo-safra-catz/chDQFqRR329">appointed</a> Clay Magouyrk and Mike Sicilia as co-CEOs, replacing Safra Catz.<a href="https://stocktwits.com/symbol/ORCL">ORCL stock</a> is up 94% year-to-date.<a href="https://stocktwits.com/symbol/AAPL">Apple Inc. (AAPL)</a>Apple shares were up nearly 4% in Monday’s afternoon session after analysts at Bank of America&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-stock-price-target-hike-dan-ives-strong-iphone-17-demand/chDQFLSR323">observed</a> that the iPhone 17’s ship times are significantly higher than those of the iPhone 16.<a href="https://stocktwits.com/symbol/AAPL">AAPL stock</a> is up 2% year-to-date.<a href="https://stocktwits.com/symbol/COMP">Compass Inc. (COMP)</a>Compass shares were down by nearly 17% in Monday’s afternoon trade after the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anywhere-real-estate-stock-rocketed-51-pre-market-today/chDQFdrR325">announcement</a> of a merger with Anywhere Real Estate Inc. (HOUS) in an all-stock transaction.<a href="https://stocktwits.com/symbol/COMP">COMP stock</a> is up 34% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/richtech-robotics-stock-price-target-hike-retail-chatter/chDQvd2R32M">Richtech Robotics Stock Sees Retail Chatter Double In A Day: Analyst Says Company's Longer-Term Visibility Is Improving</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Nvidia, Metsera, Oracle, Apple, Compass: Stocks Making The Biggest Moves Today

Nvidia’s shares were up nearly 4% in Monday’s afternoon session, hitting an all-time high, after the company announced that it will invest up to $100 billion in OpenAI as part of a new partnership with the AI startup.

Pfizer Inc. (PFE) on Monday said that it will acquire biopharmaceutical company Metsera (MTSR) for $47.50 per share in cash at closing.The upfront purchase price of $47.50 per share represents a premium of 43% from Metsera’s closing share price on Friday. The deal represents a total enterprise value of approximately $4.9 billion for Metsera.Metsera shareholders will also receive a non-transferable contingent value right (CVR) entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. The transaction is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250922965053/en/Pfizer-to-Acquire-Metsera-and-its-Next-Generation-Obesity-Portfolio">expected</a> to close in the fourth quarter of 2025, subject to the satisfaction of customary closing conditions.Shares of Metsera soared 59% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MTSR">MTSR</a> jumped from ‘bullish’ to ‘extremely bullish' territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.New York City-based Metsera is a clinical-stage biopharmaceutical company developing medicines for obesity and cardiometabolic diseases.<a href="https://stocktwits.com/symbol/PFE">Pfizer</a> said on Monday that the proposed acquisition will add four highly differentiated clinical-stage programs to Pfizer’s pipeline, including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist, and MET-233i, a monthly amylin analog candidate, in addition to two other oral GLP-1 receptor agonists expected to begin clinical trials soon. GLP-1 receptor agonists are a class of medications that mimic the effects of the body's natural hormone glucagon-like peptide-1 (GLP-1) to treat type 2 diabetes and obesity. Amylin analogs, likewise, can lead to weight loss.“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,” said Pfizer CEO Albert Bourla. Pfizer scrapped its own obesity drug candidate, Danuglipron, earlier this year.The Financial Times had on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-metsera-7b-buyout-obesity-drug-race-lilly-novo/chDQXfYR3c9">reported</a> that the two companies could announce a deal as early as Monday.While Pfizer’s stock has declined 9% so far in 2025, Metsera’s stock has risen 25.7% over the same period.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/micron-stock-gets-a-price-target-hike-from-stifel/chDQNFpR3cz">Micron Stock Gets A Price Target Hike From Stifel Ahead Of Q4 Earnings – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Metsera Stock Surges 59% Pre-Market After Pfizer Confirms Acquisition – Here Are The Details

The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday.

Pfizer is reportedly preparing to buy weight-loss biotech Metsera in a deal that could be worth as much as $7.3 billion.The New York-based drugmaker would apparently pay $47.50 a share upfront and another $22.50 tied to milestones, a sharp premium to Metsera’s recent price of $33.32. An announcement could come as early as Monday, barring last-minute delays, according to a Financial Times&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/aee4a71c-7ad6-4cde-852f-720a97542fac">report</a>,&nbsp;which cited two people familiar with the matter.The move comes after Pfizer scrapped its own obesity drug candidate, danuglipron, earlier this year. Metsera, which is listed in one of 2025’s biggest biotech IPOs, has drawn interest across the sector with MET-097i, a GLP-1 therapy that produced 11.3% weight loss over 12 weeks in a mid-stage trial.&nbsp;The company is also developing a monthly version of the shot, an amylin-based treatment aimed at avoiding muscle loss, and an oral pill. Pfizer shares, now worth about half their 2021 pandemic peak, closed Friday at $24, valuing the company at $136 billion.&nbsp;CEO Albert Bourla has been under pressure to reignite growth, with Pfizer’s last major deal being the $43 billion purchase of cancer drugmaker Seagen in 2023. A Metsera acquisition would put it in direct competition with Eli Lilly and Novo Nordisk, whose blockbuster GLP-1 drugs Zepbound and Wegovy are expanding into pill form.On Stocktwits, retail sentiment for both Pfizer and Metsera was ‘bullish’, with message volume ‘normal’ for Pfizer and ‘high’ for Metsera.One user&nbsp;labeled the reported deal value&nbsp;a “lousy premium” to Metsera’s recent trading levels and argued the company’s management may be selling too cheaply. The user added that Pfizer may have avoided a bigger gamble on Viking Therapeutics ahead of late-stage trials.<stembedurl>https://stocktwits.com/biolover/message/629465706</stembedurl>Another bullish user said that the acquisition could ultimately be seen as an $80-per-share buyout opportunity.<stembedurl>https://stocktwits.com/vu_jade/message/629466433</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> has declined 4.6% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> has risen 25.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up

Pfizer is pushing into the booming weight-loss market after its own drug setback, as rivals Eli Lilly and Novo Nordisk lead the field.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MTSR News

MTSRMetsera Inc